Patents Assigned to Sankyo Company Limited
-
Publication number: 20200216433Abstract: The present invention addresses the problem of providing a compound for prophylaxis and/or treatment of central inflammatory diseases, or a pharmacologically acceptable salt thereof. The present invention addresses a compound of a general formula (I) or a pharmacologically acceptable salt thereof as a means to solve the problem.Type: ApplicationFiled: September 28, 2018Publication date: July 9, 2020Applicant: Daiichi Sankyo Company, LimitedInventors: Keiji Saito, Katsuyoshi Nakajima, Yasuyuki Ogawa, Mitsuhiro Makino, Kaori Ito, Seiko Nagata, Hirasawa Makoto
-
Publication number: 20200207837Abstract: The present invention provides a novel peptide which comprises an amino acid sequence represented by SEQ ID NO: 23, and specifically inhibits the protease activity of a target molecule.Type: ApplicationFiled: September 6, 2018Publication date: July 2, 2020Applicant: Daiichi Sankyo Company, LimitedInventors: Daisuke Nishimiya, Masakazu Tamura
-
Publication number: 20200199179Abstract: Disclosed are compositions and method related to variants of SPINK2 that bind to targets other than an endogenous target of SPINK2. In one embodiment, a peptide is provided that comprises the amino acid sequence SEQ ID NO: 1. In further embodiments, an amino acid sequences encoded by nucleotide positions 4 to 42 and/or nucleotide positions 94 to 189 in the nucleotide sequence of SEQ ID NO: 14 flank the amino terminus and the carboxyl terminus, respectively, of the amino acid sequence. In another embodiment, a peptide is provided that comprises an amino acid sequence derived from the amino acid sequence of SEQ ID NO: 1 in which a conservative substitution, deletion, addition and/or insertion of 1 to 5 (inclusive) amino acids has occurred at amino acids other than the 1st Xaa to the 12th Xaa counting from the amino terminus.Type: ApplicationFiled: January 30, 2020Publication date: June 25, 2020Applicant: Daiichi Sankyo Company, LimitedInventors: Daisuke Nishimiya, Ryuji Hashimoto
-
Publication number: 20200173999Abstract: A method for selecting an individual to be a candidate for administration of an immune checkpoint inhibitor in treatment of a tumor, comprising: (1) a step of collecting a tumor tissue from the individual, (2) a step of determining the extent of B7-H3 expression in the tumor tissue collected in step (1), and (3) a step of selecting the individual as an individual to be a candidate for administration of the immune checkpoint inhibitor if the B7-H3 expression level is considered to be negative, is provided.Type: ApplicationFiled: December 25, 2017Publication date: June 4, 2020Applicants: KINKI UNIVERSITY, DAIICHI SANKYO COMPANY, LIMITEDInventors: Kimio Yonesaka, Kazuhiko Nakagawa, Kenji Hirotani
-
Publication number: 20200172494Abstract: Cystic fibrosis is developed through mutation of Cystic Fibrosis Transmembrane conductance Regulator (CFTR), which is one type of chloride channel. An object of the present invention is to provide compounds effective in the treatment of cystic fibrosis that open a chloride channel different from CFTR, which is the cause of the disease, and do not depend on CFTR. Compounds of the present invention are compounds or pharmaceutically acceptable salts thereof that open calcium dependent chloride channels (CaCCs) via G-protein coupled receptor 39 (GPR39) agonism to have strong chloride ion-secretory action, and are represented by the following general formula (I): General formula (I): wherein, X represents a carboxyl group or a tetrazolyl group; Q represents a C1-C3 alkylene group, an oxygen atom, a sulfur atom, etc.; G represents a phenyl group where the phenyl group may have 1 to 3 substituents independently selected from the group consisting of a halogen atom, a cyano group, a C1-C6 alkyl group, etc.Type: ApplicationFiled: December 26, 2017Publication date: June 4, 2020Applicant: Daiichi Sankyo Company, LimitedInventors: Yasuyuki Takeda, Yamato Suzuki, Toshiharu Noji, Hidenobu Murafuji, Satoshi Muneoka, Hidekazu Inoue, Bitoku Takahashi, Rie Inaba
-
Publication number: 20200171163Abstract: It is an object of the present invention to provide an antibody binding to CDH6 and having internalization activity, an antibody-drug conjugate of the antibody and a drug having antitumor activity, a pharmaceutical product comprising the antibody-drug conjugate and having therapeutic effects on a tumor, a method for treating a tumor using the antibody, the antibody-drug conjugate or the pharmaceutical product, and the like. The present invention provides an anti-CDH6 antibody having internalization activity, an antibody-drug conjugate of the antibody and a drug having antitumor activity, a pharmaceutical product comprising the antibody or the antibody-drug conjugate, and a method for treating a tumor.Type: ApplicationFiled: May 14, 2018Publication date: June 4, 2020Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Atsuko SAITO, Tsuyoshi HIRATA, Kensuke NAKAMURA
-
Patent number: 10654821Abstract: An object of the present invention is to provide a compound having an anti-inflammatory activity or a pharmacologically acceptable salt thereof. The solution of the present invention is a compound of general formula (1) or a pharmacologically acceptable salt thereof. wherein the symbols in the formula are defined below: R1: e.g., a C1-C6 alkyl group; R2: a C1-C6 alkyl group; A: e.g., an oxygen atom; and R3: e.g., a C1-C6 alkyl group.Type: GrantFiled: September 5, 2019Date of Patent: May 19, 2020Assignee: Daiichi Sankyo Company, LimitedInventors: Keiji Saito, Katsuyoshi Nakajima, Toru Taniguchi, Osamu Iwamoto, Satoshi Shibuya, Yasuyuki Ogawa, Kazumasa Aoki, Nobuya Kurikawa, Shinji Tanaka, Momoko Ogitani, Eriko Kioi, Kaori Ito, Natsumi Nishihama, Tsuyoshi Mikkaichi, Wataru Saitoh
-
Patent number: 10647769Abstract: To provide a novel antibody. Provided is a monoclonal antibody or a binding fragment thereof that binds to domain 3 of human LAG-3 and has one or more of the properties described in (ii) to (v), and the properties described in (i) and (vi) below: (i) having in vitro ADCC activity; (ii) reducing the number of LAG-3 positive cells in vivo in low fucose form; (iii) suppressing experimental autoimmune encephalomyelitis in vivo in low fucose form; (iv) binding to human activated T cells; (v) human LAG-3 binds to human major histocompatibility complex class II molecules in the presence of the antibody or the binding fragment thereof; and (vi) the presence of the antibody or the binding fragment thereof allowing human LAG-3 to exert a human T cell suppression function.Type: GrantFiled: November 7, 2019Date of Patent: May 12, 2020Assignee: Daiichi Sankyo Company, LimitedInventors: Ryuta Mukasa, Kensuke Nakamura, Sumie Muramatsu, Naoyuki Makita
-
Publication number: 20200131230Abstract: Provided is a compound that can promote angiogenesis by inhibiting the function of TSP1, and is useful for the treatment or prophylaxis of diseases such as critical limb ischemia.Type: ApplicationFiled: September 13, 2017Publication date: April 30, 2020Applicants: Daiichi Sankyo Company, Limited, PeptiDream Inc.Inventors: Takahiro YAMAGUCHI, Yutaka MORI, Hironao SAITO, Hideki KUBOTA, Akihiro FURUKAWA, Eri OTSUKA, Yutaka ISHIGAI, Hiroshi IJIRI, Patrick REID
-
Patent number: 10633346Abstract: A method for producing a compound (4), which comprises allowing a compound (1) to react with hydrogen gas in an inert solvent, in the presence of a specific chiral ligand and a ruthenium catalyst, or in the presence of an asymmetric transition metal complex catalyst previously generated from the chiral ligand and the ruthenium catalyst.Type: GrantFiled: October 22, 2018Date of Patent: April 28, 2020Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Masaki Hayashi, Kazutoshi Ukai
-
Publication number: 20200123253Abstract: To provide a novel antibody. Provided is a monoclonal antibody or a binding fragment thereof that binds to domain 3 of human LAG-3 and has one or more of the properties described in (ii) to (v), and the properties described in (i) and (vi) below: (i) having in vitro ADCC activity; (ii) reducing the number of LAG-3 positive cells in vivo in low fucose form; (iii) suppressing experimental autoimmune encephalomyelitis in vivo in low fucose form; (iv) binding to human activated T cells; (v) human LAG-3 binds to human major histocompatibility complex class II molecules in the presence of the antibody or the binding fragment thereof; and (vi) the presence of the antibody or the binding fragment thereof allowing human LAG-3 to exert a human T cell suppression function.Type: ApplicationFiled: November 7, 2019Publication date: April 23, 2020Applicant: Daiichi Sankyo Company, LimitedInventors: Ryuta Mukasa, Kensuke Nakamura, Sumie Muramatsu, Naoyuki Makita
-
Publication number: 20200115446Abstract: An object of the present invention is to provide a pharmaceutical agent for the treatment and/or prophylaxis of pediatric osteoporosis without causing bone growth disorder in a subject to be medicated. A pharmaceutical composition for the treatment and/or prophylaxis of pediatric osteoporosis contains an antibody or a functional fragment thereof which binds to Siglec-15 and has activity of suppressing formation of osteoclasts and/or bone resorption by osteoclasts.Type: ApplicationFiled: June 29, 2018Publication date: April 16, 2020Applicants: NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY, DAIICHI SANKYO COMPANY, LIMITEDInventors: Masahiko TAKAHATA, Dai SATO, Masahiro OTA, Tomohiro SHIMIZU, Chie FUKUDA, Eisuke TSUDA
-
Publication number: 20200113842Abstract: The tablet of the present invention is a tablet 1 having a cup portion 12 formed at least above or below a side portion 11, wherein the outer surface of the cup portion 12 includes first, second and third curved surfaces 12a, 12b and 12c having different curvatures R1, R2 and R3, the first curved surface 12a is at least continuous with the second curved surface 12b, the second curved surface 12b is continuous with the first curved surface 12a and the third curved surface 12c, and the third curved surface 12c is at least continuous with the second curved surface 12b.Type: ApplicationFiled: June 26, 2018Publication date: April 16, 2020Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventor: Kazuhisa SEKINE
-
Patent number: 10603285Abstract: An object of the present invention is to provide [(1R,5S,6S)-6-(aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-en-6-yl]acetic acid monobenzenesulfonate as a stabilized pharmaceutical solid preparation, and also to provide a method for preparing the stabilized pharmaceutical solid preparation. The object can be attained by a pharmaceutical solid preparation comprising [(1R,5S,6S)-6-(aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-en-6-yl]acetic acid monobenzenesulfonate which is compound represented by the following formula (I) in combination with (i) one or two or more components selected from the group consisting of D-mannitol, lactose, corn starch, and crystalline cellulose, (ii) carmellose calcium, and (iii) colorants.Type: GrantFiled: March 17, 2016Date of Patent: March 31, 2020Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Shinichiro Tajiri, Shinji Yoshinaga, Yurika Ozaki
-
Publication number: 20200085946Abstract: The present invention provides a pharmaceutical composition or a diagnostic composition targeting human fibroblast growth factor receptor 2 (hFGFR2).Type: ApplicationFiled: November 19, 2019Publication date: March 19, 2020Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Chigusa YOSHIMURA, Reimi KAWAIDA, Kokichi HONDA
-
Publication number: 20200087321Abstract: The present invention relates to a compound or a pharmacologically acceptable salt thereof having excellent tissue non-specific alkaline phosphatase inhibitory activity. The present invention provides a compound represented by the formula (I) or a pharmacologically acceptable salt thereof.Type: ApplicationFiled: December 22, 2017Publication date: March 19, 2020Applicants: DAIICHI SANKYO COMPANY, LIMITED, SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTEInventors: Shojiro Miyazaki, Masaharu Inui, Yasunobu Kurosaki, Yuko Yamamoto, Masanori Izumi, Kaori Soma, Anthony Pinkerton, Masamichi Kishida
-
Publication number: 20200080080Abstract: The present invention aims at establishing a molecular therapy for Alport syndrome. The present invention provides an oligonucleotide of 15-30 bp comprising a nucleotide sequence complementary to the cDNA of COL4A5 gene, wherein the oligonucleotide is capable of inducing skipping of an exon which has a truncating mutation found in COL4A5 gene in Alport syndrome patients and whose nucleotide number is a multiple of 3, a pharmaceutically acceptable salt thereof, or a solvate thereof. Also provided is a pharmaceutical drug comprising the above oligonucleotide, a pharmaceutically acceptable salt thereof, or a solvate thereof (therapeutic drug for Alport syndrome).Type: ApplicationFiled: December 25, 2017Publication date: March 12, 2020Applicants: DAIICHI SANKYO COMPANY, LIMITED, NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITYInventors: Kazumoto IIJIMA, Kandai NOZU, Akemi SHONO, Makoto KOIZUMI, Yoshiyuki ONISHI, Kiyosumi TAKAISHI, Tomomi ADACHI
-
Publication number: 20200062765Abstract: Provided is a novel and industrially useful method for producing a 3, 6-disubstituted imidazo[1, 2-b]pyridazine derivative. The present invention provides a method for producing a 3, 6-disubstituted imidazo[1, 2-b]pyridazine derivative, which uses 6-fluoroimidazo[1, 2-b]pyridazine as a starting material, while using an aromatic substitution reaction that utilizes C—H activation by means of palladium.Type: ApplicationFiled: March 13, 2018Publication date: February 27, 2020Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Ryoji KOIKE, Yoshifumi HACHISU, Takafumi KITAWAKI, Shohei SHIRAISHI
-
Publication number: 20200061031Abstract: [Problem] To provide a therapeutic agent and a therapeutic method for EGFR-TKI-resistant non-small cell lung cancer. [Solution] Provided are: a therapeutic agent that contains an anti-HER3 antibody-drug conjugate as an active ingredient, or a therapeutic method characterized by administering an anti-HER3 antibody-drug conjugate.Type: ApplicationFiled: February 27, 2018Publication date: February 27, 2020Applicants: KINKI UNIVERSITY, DAIICHI SANKYO COMPANY, LIMITEDInventors: Kimio YONESAKA, Kazuhiko NAKAGAWA, Kenji HIROTANI
-
Patent number: 10570109Abstract: An object of the present invention is to provide a compound having an anti-inflammatory activity or a pharmacologically acceptable salt thereof. The solution of the present invention is a compound of general formula (1) or a pharmacologically acceptable salt thereof. wherein the symbols in the formula are defined below: R1: e.g., a C1-C6 alkyl group; R2: a C1-C6 alkyl group; A: e.g., an oxygen atom; and R3: e.g., a C1-C6 alkyl group.Type: GrantFiled: March 29, 2017Date of Patent: February 25, 2020Assignee: Daiichi Sankyo Company, LimitedInventors: Keiji Saito, Katsuyoshi Nakajima, Toru Taniguchi, Osamu Iwamoto, Satoshi Shibuya, Yasuyuki Ogawa, Kazumasa Aoki, Nobuya Kurikawa, Shinji Tanaka, Momoko Ogitani, Eriko Kioi, Kaori Ito, Natsumi Nishihama, Tsuyoshi Mikkaichi, Wataru Saitoh